Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3

Oncoimmunology. 2020 May 21;9(1):1761205. doi: 10.1080/2162402X.2020.1761205.

Abstract

The success of CD8+ T cell-based cancer immunotherapy emphasizes the importance of understanding the mechanisms of generation of MHC-I peptide ligands and the possible pathways of tumor cell escape from immunosurveillance. Recently, we showed that peptides generated in the nucleus during a pioneer round of mRNA translation (pioneer translation products, or PTPs) are an important source of tumor specific peptides which correlates with the aberrant splicing and transcription events associated with oncogenesis. Here we show that up-regulation of PSME3 proteasome activator in cancer cells results in increased destruction of PTP-derived peptides in the nucleus thus enabling cancer cell to subvert immunosurveillance. These findings unveil a previously unexpected role for PSME3 in antigen processing and identify PSME3 as a druggable target to improve the efficacy of cancer immunotherapy.

Keywords: Tumor immune responses; activator PSME3; pioneer translation products; proteasome regulations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen Presentation*
  • Histocompatibility Antigens Class I
  • Monitoring, Immunologic
  • Proteasome Endopeptidase Complex* / genetics
  • Tumor Escape

Substances

  • Histocompatibility Antigens Class I
  • Proteasome Endopeptidase Complex

Grants and funding

This work was supported by the The Avenir program (INSERM); la ligue contre le cancer; Fondation ARC; Fondation Gustave Roussy.